<DOC>
	<DOCNO>NCT02768948</DOCNO>
	<brief_summary>The severity diabetic nephropathy proportional proteinuria rate degree renal interstitial fibrosis . Despite many treatment available today , diabetic nephropathy responsible quarter case end-stage renal disease ( ESRD ) require use renal replacement therapy kidney transplantation . It develop follow : chronic hyperglycemia diabetes abyss renal glomerulus allow protein urine room . In response , tubular epithelium produce monocyte chemoattractant protein-1 ( MCP-1 ) attract monocyte circulate renal interstitium . Monocytes differentiate M1 M2 macrophage . M1 macrophage increase MCP-1 production M2 macrophages produce transform growth factor beta ( TGF-β ) pro-fibrogenic . Renal fibrosis negatively correlate glomerular filtration rate proportional number nephron . The decrease number nephron majorises secondarily proteinuria onset focal segmental glomerulosclerosis lesion . Production MCP-1 increase renal proteinuria M1 macrophage earn kidney reinforce production MCP-1 , fibrosis worsens M2 macrophage infiltrate turn kidney produce TGF -β . A way limit renal fibrosis would decrease renal monocytic infiltration promote differentiation monocyte towards macrophage M2 . Although numerous , M2 macrophages long benefit kidney decline M1 macrophage decrease renal MCP-1 production . Ex vivo IL1-β orient differentiation monocytes towards macrophage M1 IL-4 M2 . By con vivo , differentiate factor poorly know . It remarkable metformin telmisartan increase M2 macrophages M1 macrophage decrease , respectively , human mice . Moreover , telmisartan reduces proteinuria losartan diabetic nephropathy human Metformin decrease amount TGF-β intra-renal mouse . This effect telmisartan independent type 1 receptor angiotensin II ( AT1R ) since obtain losartan . Telmisartan partial agonist peroxisome proliferator-activated receptor gamma ( PPARgamma ) , work assumption telmisartan foster transition monocyte macrophage M2 form , limit recruitment monocytes kidney therefore proteinuria renal fibrosis . To show , compare ability monocyte differentiate ex vivo M1 M2 macrophages diabetic nephropathy patient treat losartan telmisartan characterize role PPARgamma monocyte / macrophage transition . Finally , compare urinary excretion amino terminal propeptide procollagen type 3 ( PIIINP ) , consider marker renal fibrosis patient receive losartan telmisartan .</brief_summary>
	<brief_title>Telmisartan Promotes Differentiation Monocytes Into Macrophages M2 Diabetic Nephropathy ?</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Type 2 diabetes ; Proteinuria ≥ 0.5 g / g motivate prescription ACE inhibitor ARA2 full dose ; Processing statin ; Processing metformin ; court treatment GLP1 agonists DPP4 inhibitor ; About sign informed consent ; affiliate social security issue Diabetic nephropathy ; GFR &lt; 30 ml / min / 1.73 m2 ; Type 1 diabetes ; Maturity Onset Diabetes Youth ( MODY ) ; Use telmisartan 6 month prior enrollment ; Liver cirrhosis ( potential production PIIINP ) ; chronic inflammatory disease ; active cancer ; immunosuppression ; Pregnant breastfeed woman ( urine pregnancy test perform woman childbearing age ) ; adult person guardianship ; Hospitalized person without consent protect law ; person deprive liberty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>